5α-dihydro-11-keto Testosterone
(Synonyms: 17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮,5α-Androstane-3,11-dione-17β-ol,11-keto Dihydrotestosterone,17β-hydroxy-5α-Androstane-3,11-dione) 目录号 : GC15774An Analytical Reference Standard
Cas No.:32694-37-4
Sample solution is provided at 25 µL, 10mM.
5α-dihydro-11-keto Testosterone (11KDHT) is a full androgen receptor agonist comparable to dihydrotestosterone (DHT) [1][2][3].
Androgen receptor is a nuclear receptor that is activated by the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Androgen receptor acts as a DNA-binding transcription factor that regulates gene expression.
5α-dihydro-11-keto Testosterone is a full AR agonist exhibiting similar activity to DHT at 1 nM [3]. 5α-dihydro-11-keto Testosterone is a metabolite of 11-ketotestosterone and 11β-hydroxyandrostenedione (11OHA4), which is metabolized by 11βHSD, 17βHSD and SRD5A, resulted in significant increase in androgenic activity at a physiologically relevant concentration. 5α-dihydro-11-keto Testosterone represented a novel androgen which may play an important role in driving AR-mediated gene expression [1]. In COS-1 cells, 5α-dihydro-11-keto Testosterone exhibited activity comparable to DHT (96%). 5α-dihydro-11-keto Testosterone might be implicated in driving castration-resistant prostate cancer (CRPC) in the absence of testicular T [3].
References:
[1]. Bloem LM, Storbeck KH, Schloms L, et al. 11β-hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. Molecules. 2013 Oct 25;18(11):13228-44.
[2]. Swart AC, Storbeck KH. 11β-Hydroxyandrostenedione: Downstream metabolism by 11βHSD, 17βHSD and SRD5A produces novel substrates in familiar pathways. Mol Cell Endocrinol. 2015 Jun 15;408:114-23.
[3]. Storbeck KH, Bloem LM, Africander D, et al. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer Mol Cell Endocrinol. 2013 Sep 5;377(1-2):135-46.
Cas No. | 32694-37-4 | SDF | |
别名 | 17BETA-羟基-5ALPHA-雄甾烷-3,11-二酮,5α-Androstane-3,11-dione-17β-ol,11-keto Dihydrotestosterone,17β-hydroxy-5α-Androstane-3,11-dione | ||
化学名 | (5α,17β)-17-hydroxy-androstane-3,11-dione | ||
Canonical SMILES | O[C@H]1CC[C@@]([C@]1(C)C2)([H])[C@]3([H])CC[C@@]4([H])CC(CC[C@]4(C)[C@@]3([H])C2=O)=O | ||
分子式 | C19H28O3 | 分子量 | 304.4 |
溶解度 | DMF: 20 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:10): 0.09 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.2852 mL | 16.4258 mL | 32.8515 mL |
5 mM | 0.657 mL | 3.2852 mL | 6.5703 mL |
10 mM | 0.3285 mL | 1.6426 mL | 3.2852 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet